The GRADUATE I clinical study will assess how safe and effective an investigational drug is at slowing the progression of mild cognitive impairment and mild Alzheimer’s disease.
What this study involves
The total length of the GRADUATE I study is up to 3 years, including screening and follow-up. The dosing period of the study will last for 2 years, during which half of the participants will be given the investigational drug and half will be given a placebo (a dummy drug that contains no active ingredients). These will be given as subcutaneous (under the skin) injections at a study clinic, once every 2 to 4 weeks. Participants will not know which group they have been assigned to. But please be assured that every participant will receive the same close monitoring throughout via regular clinic visits, regardless of their group.
What else should I know?
All study-related drugs and assessments will be provided at no cost to participants. Travel reimbursement may also be included. Of course, taking part in a clinical study is a personal decision and no one has to join if they don’t want to. It’s also important to know that if participants join the study and then change their mind, they can leave at any time without any impact on their usual healthcare.
To qualify, participants must:
- Be 50 to 90 years old
- Have mild Alzheimer’s disease or memory problems that may be the early symptoms of the condition
- Have someone they see frequently and who is willing to act as their Study Partner